Iovance Biotherapeutics (IOVA) falls on data for lifileucel in advanced melanoma
Reported clinical results from its C-144-01 clinical study of lifileucel in patients with advanced melanoma. Among results, in registrational Cohort 4, the objective response rate was 29%, with three complete responses and 22 partial responses, while the median duration of response was 10.4 months with a median study follow-up of 23.5 months. In Cohort 2, the ORR was 35%, with five complete responses and 18 partial responses, and the median DOR in Cohort 2 was not reached with a median study follow-up of 36.6 months.
No comments:
Post a Comment